Browsing Over 990 Presentations

Sort By

Charting the course for the stage III NSCLC patient (ID 1780)

What’s new in metastatic pancreatic cancer management? (ID 1785)

Introduction of Speaker (ID 1791)

The clinical significance of comprehensive genomic profiling (ID 1796)

Expert Opinion on ‘PARP inhibitors as targeted therapy for personalized medicine’ - Panel Discussion (ID 1882)

Welcome, introductions and objectives of the session (ID 1801)

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC ESMO Colloquium

Introduction

Lecture Time
12:45 PM - 12:50 PM
Session Name
ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Speakers
  • Ross A. Soo
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM
Authors
  • Ross A. Soo

Introduction (ID 1783)

Introduction of Speaker (ID 1789)

Q&A (ID 1794)

Singapore’s journey with precision oncology (ID 1799)

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC ESMO Colloquium

EGFR mutant mNSCLC: Single agent or in combination?

Lecture Time
01:15 PM - 01:40 PM
Session Name
ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Speakers
  • Fabrice Barlesi
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM
Authors
  • Fabrice Barlesi